Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

(2012) A. Neumann et al.   DIABETOLOGIA

Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?

(2012) Daniel Merk et al.   Future Medicinal Chemistry

New Insights into the Role of Peroxisome Proliferator-Activated Receptors in Regulating the Inflammatory Response after Tissue Injury

(2012) Miriam D. Neher et al.   PPAR Research

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

(2011) Jang Hyun Choi et al.   NATURE

Safer PPARγ-targeted drugs on the horizon?

(2011) Sarah Crunkhorn   NATURE REVIEWS DRUG DISCOVERY

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects

(2010) Mi-Kyung Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon

(2010) L. Peyrin-Biroulet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

(2009) Mi-Kyung Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARα agonists

(2009) Heiko Zettl et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structural Basis for the Design of PPAR-γ Ligands: A Survey on Quantitative Structure- Activity Relationships

(2009) Costas Giaginis et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?

(2008) P. Feldman et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

(2008) Naomi Shimazaki et al.   EUROPEAN JOURNAL OF CANCER

PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo

(2008) Mi-Kyung Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Thematic Review Series: Skin Lipids.Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology

(2008) Matthias Schmuth et al.   JOURNAL OF LIPID RESEARCH

Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor β/δ (NR1C2) Antagonist

(2007) Barry G. Shearer et al.   MOLECULAR ENDOCRINOLOGY